Business Roundtable
Valuing a Technology Platform
Monday, February 11, 2008
9:30 AM
Conrad Suite
Platform deals are definitely back, demonstrated by multiple high-profile acquisitions and partnership deals in 2007. These platforms range from new drug discovery landscapes like RNAi, TLRs, and NNRs to new tools, technologies, or diagnostics that make drugs better or enhance the discovery process. What has changed since the bottom dropped out of this sector? What are the drivers that will keep this sector alive and growing?
Moderators
- Adam Goldston; Sr. Vice President, Investment Banking, Jefferies and Co.
Panelists
- Stephen Hoffman, MD, PhD; Managing Director, Skyline Ventures
- Greg Wiederrech; Vice President and Head of External Scientific Affairs, Merck & Co.
- Stephen Keane; Senior VP of Business Development, Ambit Biosciences
- Mark Edwards; CEO, Recombinant Capital